BACKGROUND: Driveline infection (DLI) is one of the leading causes for unplanned re-admissions of patients undergoing therapy with left ventricular assist devices (LVAD). In previous studies our group was able to show that a double tunneling implantation technique could significantly reduce infection rates one year after implantation. We now report the results of the five-year-follow up of patients receiving the double tunneling technique. METHODS: We retrospectively analyzed patients receiving LVAD therapy with the HeartWare ventricular assist device (HVAD) (Medtronic, Minnesota, MN, USA) LVAD. For 36 patients (group 1) the driveline was tunneled via a conventional technique. In the remaining 33 patients (group 2) the drivelines were implanted by means of a double tunneling technique. The double tunnel driveline technique involved placement of the driveline in the sheath of the rectus muscle in the umbilical direction and then subcutaneously to the left (alternatively right) upper quadrant. We retrospectively compared both groups. Primary outcome parameters were infection rate and mortality. RESULTS: Five years after LVAD implantation the DLI rate of patients operated by a double tunneling technique was significantly lower than in the conventional technique group [61% (n=22) group 1 vs. 30% (n=10) group 2, P=0.004]. The 5-year mortality was lower in group 2 [42% (n=15) group 1 vs. 27% (n=9) group 2] but did not achieve statistical significance (P=0.10). The days of LVAD support between the two groups were comparable (1,275.56±885.89 group 1 vs. 1,321.94±711.37 group 2). The tunnel technique itself showed to be strongly associated with the occurrence of DLI. Other elevated variables are liver disease and dilated cardiomyopathy as primary disease. CONCLUSIONS: Double tunneling technique for driveline implantation leads to significantly lowered infection rates after 5 years of LVAD therapy and it is associated with a lower mortality.
BACKGROUND: Driveline infection (DLI) is one of the leading causes for unplanned re-admissions of patients undergoing therapy with left ventricular assist devices (LVAD). In previous studies our group was able to show that a double tunneling implantation technique could significantly reduce infection rates one year after implantation. We now report the results of the five-year-follow up of patients receiving the double tunneling technique. METHODS: We retrospectively analyzed patients receiving LVAD therapy with the HeartWare ventricular assist device (HVAD) (Medtronic, Minnesota, MN, USA) LVAD. For 36 patients (group 1) the driveline was tunneled via a conventional technique. In the remaining 33 patients (group 2) the drivelines were implanted by means of a double tunneling technique. The double tunnel driveline technique involved placement of the driveline in the sheath of the rectus muscle in the umbilical direction and then subcutaneously to the left (alternatively right) upper quadrant. We retrospectively compared both groups. Primary outcome parameters were infection rate and mortality. RESULTS: Five years after LVAD implantation the DLI rate of patients operated by a double tunneling technique was significantly lower than in the conventional technique group [61% (n=22) group 1 vs. 30% (n=10) group 2, P=0.004]. The 5-year mortality was lower in group 2 [42% (n=15) group 1 vs. 27% (n=9) group 2] but did not achieve statistical significance (P=0.10). The days of LVAD support between the two groups were comparable (1,275.56±885.89 group 1 vs. 1,321.94±711.37 group 2). The tunnel technique itself showed to be strongly associated with the occurrence of DLI. Other elevated variables are liver disease and dilated cardiomyopathy as primary disease. CONCLUSIONS: Double tunneling technique for driveline implantation leads to significantly lowered infection rates after 5 years of LVAD therapy and it is associated with a lower mortality.
Authors: Margaret M Hannan; Shahid Husain; Frauke Mattner; Lara Danziger-Isakov; Richard J Drew; G Ralph Corey; Stephan Schueler; William L Holman; Leo P Lawler; Steve M Gordon; Niall G Mahon; John M Herre; Kate Gould; Jose G Montoya; Robert F Padera; Robert L Kormos; John V Conte; Martha L Mooney Journal: J Heart Lung Transplant Date: 2011-04 Impact factor: 10.247
Authors: Felix Fleissner; Murat Avsar; Doris Malehsa; Martin Strueber; Axel Haverich; Jan D Schmitto Journal: Artif Organs Date: 2013-01 Impact factor: 3.094
Authors: Daniel J Goldstein; Ranjit John; Christopher Salerno; Scott Silvestry; Nader Moazami; Douglas Horstmanshof; Robert Adamson; Andrew Boyle; Mark Zucker; Joseph Rogers; Stuart Russell; James Long; Francis Pagani; Ulrich Jorde Journal: J Heart Lung Transplant Date: 2013-07 Impact factor: 10.247
Authors: Jasmin S Hanke; Sebastian V Rojas; Günes Dogan; Christina Feldmann; Erik Beckmann; Ezin Deniz; Bettina Wiegmann; Jana-Elena Michaelis; L Christian Napp; Dominik Berliner; Malakh Shrestha; Johann Bauersachs; Axel Haverich; Jan D Schmitto Journal: Eur J Cardiothorac Surg Date: 2017-05-01 Impact factor: 4.191
Authors: Supriya Shore; Michael J Pienta; Tessa M F Watt; Gardner Yost; Whitney A Townsend; Lourdes Cabrera; Michael D Fetters; Carol Chenoweth; Keith D Aaronson; Francis D Pagani; Donald S Likosky Journal: J Heart Lung Transplant Date: 2021-10-22 Impact factor: 13.569
Authors: Tomasz Dziodzio; Mariusz Kuśmierczyk; Andrzej Juraszek; Mikołaj Smólski; Piotr Kołsut; Jarosław Szymański; Paweł Litwiński; Krzysztof Kuśmierski; Joanna Zakrzewska-Koperska; Maciej Sterliński Journal: J Cardiothorac Surg Date: 2021-08-03 Impact factor: 1.637
Authors: Jane E Wilcox; Rebecca S Harap; Valentina Stosor; Elaine R Cohen; Kathleen L Grady; Kenzie A Cameron; Denise M Scholtens; Diane B Wayne; Kerry B Shanklin; Gretchen P Nonog; Lauren E Schulze; Alison M Jirak; Grace C Magliola; Jeffrey H Barsuk Journal: J Cardiovasc Nurs Date: 2022 May-Jun 01 Impact factor: 2.468
Authors: Andreas P Kourouklis; Julius Kaemmel; Xi Wu; Evgenij Potapov; Nikola Cesarovic; Aldo Ferrari; Christoph Starck; Volkmar Falk; Edoardo Mazza Journal: Eur Biophys J Date: 2021-09-03 Impact factor: 1.733